Spironolactone, a blood pressure medication that has been on the market since the 1950s, is now one of the most effective treatments available for hormonal acne in women — and most people have never heard of it. Originally developed to treat heart failure, hypertension, and fluid retention, this mineralocorticoid receptor antagonist works by blocking androgen receptors and reducing the sebum production that drives breakouts along the jawline, chin, and lower face. Retrospective studies involving nearly 1,500 patients show that 80 to 85 percent of women on spironolactone achieved clearance or near-clearance of their acne, numbers that rival or exceed what most standard treatments deliver. The growth in prescribing has been dramatic.
According to a study published in JAMA Dermatology, prescribing rates of spironolactone for acne in women rose by nearly 300 percent from 2017 to 2020. By that year, dermatologists were writing prescriptions for spironolactone at rates comparable to antibiotics, which had long been the default oral treatment for moderate to severe acne. Yet despite those numbers, experts at the American Academy of Dermatology have noted the drug remains underused relative to its demonstrated efficacy. This article covers how spironolactone works against acne, the clinical evidence behind it, how it compares to antibiotics, what the dosing looks like, who should and should not take it, and what ongoing research may tell us next.
Table of Contents
- How Does a Blood Pressure Drug End Up Clearing Skin?
- What Does the Clinical Evidence Actually Show?
- Spironolactone vs. Doxycycline — What the Head-to-Head Data Says
- Dosing, Timeline, and What to Realistically Expect
- Who Should Not Take Spironolactone — and Why Safety Matters
- Where Spironolactone Fits in Treatment Guidelines
- What Ongoing Research Could Change
- Conclusion
- Frequently Asked Questions
How Does a Blood Pressure Drug End Up Clearing Skin?
The connection between blood pressure and breakouts is less strange than it sounds. Spironolactone’s primary mechanism involves blocking aldosterone, a hormone involved in regulating sodium and fluid balance. But aldosterone is not the only hormone it interferes with. Spironolactone also blocks androgen receptors — the same receptors activated by testosterone and its derivatives. In women with hormonal acne, androgens stimulate the sebaceous glands to overproduce oil, which clogs pores and creates the inflammatory lesions that cluster around the jaw and chin. By dampening that androgen signal, spironolactone reduces sebum output at the source, rather than simply treating the downstream bacterial infection or inflammation the way antibiotics do.
This makes spironolactone fundamentally different from most acne treatments. Topical retinoids speed up skin cell turnover. Benzoyl peroxide kills bacteria. Antibiotics like doxycycline suppress the inflammatory response. But none of those address the hormonal driver that, for many women, is the root cause of persistent adult acne. A woman in her 30s who has cycled through topical treatments, multiple rounds of antibiotics, and perhaps even isotretinoin without lasting results may find that spironolactone finally works because it targets the mechanism those other drugs miss entirely. The drug is not FDA-approved for acne — it is prescribed off-label — but it is included in the American Academy of Dermatology’s official treatment guidelines, generally as a second-line option when first-line treatments prove insufficient.
What Does the Clinical Evidence Actually Show?
The numbers behind spironolactone’s efficacy are unusually strong for a dermatologic treatment. A 2025 systematic review and meta-analysis of randomized, placebo-controlled trials found that spironolactone significantly improved acne with an odds ratio of 6.59 (95 percent confidence interval: 3.50 to 12.43; p < 0.00001) on objective assessments compared to placebo. A separate meta-analysis reported a pooled odds ratio of 2.51 for treatment success when compared against placebo or doxycycline. In one study of 110 female patients, 85 percent showed improvement and 55 percent experienced complete clearing. A larger retrospective review found that 217 of 227 women — 95.6 percent — at a mean dose of 104 milligrams per day achieved complete clearance.
In another cohort of 395 women at a median dose of 100 milligrams per day, 361 patients (91.4 percent) had a complete or partial response. However, these results come with important context. Most of the strongest data comes from retrospective reviews rather than large-scale randomized controlled trials, which means the evidence, while compelling, is not as methodologically ironclad as what supports some other medications. The women in these studies were selected because they had hormonal acne patterns, so the results do not necessarily generalize to all acne types. If your breakouts are primarily comedonal (blackheads and whiteheads without significant inflammation) or driven by factors other than hormonal fluctuations, spironolactone is unlikely to be the right fit. The drug works best for the specific subset of acne driven by androgen activity, and a dermatologist’s clinical judgment in identifying that pattern matters.
Spironolactone vs. Doxycycline — What the Head-to-Head Data Says
For years, the obvious question was how spironolactone stacks up against antibiotics in a direct comparison rather than against placebo alone. The FASCE study, a multicenter, randomized, double-blind trial published in the British Journal of Dermatology in 2024, provided an answer. Researchers directly compared spironolactone to doxycycline in adult women with moderate acne. At month four, spironolactone was 1.37 times more successful than doxycycline.
By month six, that gap widened considerably: spironolactone was 2.87 times more successful. Beyond raw efficacy, the FASCE trial found that quality of life scores and drug tolerance were both better in the spironolactone group. This matters because doxycycline, while effective, carries well-known downsides: gastrointestinal upset, sun sensitivity, esophageal irritation, and the broader concern about antibiotic resistance that comes with long-term antibiotic use for a non-infectious condition. Spironolactone sidesteps all of those issues. For a woman who has been on repeated courses of doxycycline or minocycline with only partial improvement and recurring flares once the antibiotic is stopped, spironolactone offers a mechanistically different approach that does not contribute to the growing public health problem of antimicrobial resistance.
Dosing, Timeline, and What to Realistically Expect
Effective doses of spironolactone for acne range from 50 to 200 milligrams daily, with most studies centering on 100 milligrams per day as the standard therapeutic dose. The relationship between dose and efficacy is dose-dependent, meaning that doses above 100 milligrams per day may provide additional benefit for women who do not fully respond at lower levels. Most dermatologists start at 25 or 50 milligrams and titrate upward, both to assess tolerance and because the drug takes time to work — typically two to three months before visible improvement, with full results often not apparent until six months in. This slow onset is one of the tradeoffs patients need to understand upfront.
Unlike a course of antibiotics that may begin reducing inflammation within a week or two, spironolactone requires patience. The initial months can be discouraging, especially for someone who has already waited through multiple failed treatments. Many dermatologists will combine spironolactone with a topical retinoid or benzoyl peroxide during the early months to manage breakouts while the systemic medication builds toward its full effect. The other significant tradeoff is that spironolactone is generally a maintenance medication: acne often returns when the drug is discontinued, which means many women stay on it long-term, sometimes for years.
Who Should Not Take Spironolactone — and Why Safety Matters
Spironolactone is only prescribed to women. Its anti-androgen effects make it contraindicated in men, where blocking testosterone activity would cause breast tissue growth, sexual dysfunction, and other unacceptable side effects. In women, meta-analyses have found no statistically significant increase in adverse effects — including menstrual irregularities and breast tenderness — compared to placebo, making it very well tolerated overall. But the drug does carry a critical safety concern: it is teratogenic, meaning it can cause birth defects, specifically the feminization of a male fetus.
Any woman taking spironolactone must use reliable contraception, and the drug is not prescribed to women who are pregnant or planning to become pregnant. Because spironolactone is a potassium-sparing diuretic, there is a theoretical risk of hyperkalemia, or elevated potassium levels. In practice, this risk is low in young, otherwise healthy women with normal kidney function, and routine potassium monitoring is debated among dermatologists — some check levels periodically, while others have moved away from frequent monitoring in low-risk patients. However, women with kidney disease, those taking potassium supplements, or those on other medications that raise potassium levels (such as ACE inhibitors or ARBs) require closer monitoring. If you fall into any of these categories, the conversation with your prescriber about risks becomes more nuanced than the standard case.
Where Spironolactone Fits in Treatment Guidelines
The American Academy of Dermatology includes spironolactone in its official acne treatment guidelines, positioning it as a second-line option for women whose acne does not respond adequately to topical treatments or oral antibiotics. A 2025 evidence review published in JAAD Reviews provides updated practical recommendations for dermatologists considering the drug.
In clinical practice, spironolactone tends to be most useful for women in their 20s, 30s, and 40s with acne that flares in relation to their menstrual cycle, concentrates along the lower face and jawline, and has not responded to conventional approaches. It fills a gap between antibiotics, which work but carry resistance concerns and tend to lose efficacy over time, and isotretinoin, which is highly effective but comes with significant side effects and monitoring requirements.
What Ongoing Research Could Change
A clinical trial at UCSF (NCT04582383) comparing spironolactone directly to doxycycline for acne has an estimated completion date of July 2026. That trial will add to the evidence base established by the FASCE study and could further shift prescribing patterns if the results are consistent.
Given the trajectory — a 300 percent increase in prescribing over just three years, head-to-head superiority over antibiotics in the FASCE trial, and strong safety data from meta-analyses — spironolactone appears to be moving from an underused second-line option toward a more prominent role in first-line management of hormonal acne in women. Whether it eventually receives FDA approval specifically for acne remains an open question, but the clinical evidence supporting its use continues to strengthen with each new study.
Conclusion
Spironolactone represents a genuine paradigm shift in how hormonal acne is treated in women. A drug designed for heart failure and high blood pressure turns out to be more effective than the antibiotics dermatologists have relied on for decades, with fewer side effects and no contribution to antibiotic resistance. The clinical numbers — odds ratios above 6 compared to placebo, clearance rates above 90 percent in large retrospective studies, and measurable superiority over doxycycline in head-to-head trials — make a compelling case that goes well beyond anecdote.
For women dealing with persistent hormonal acne that has not responded to topical treatments or antibiotics, a conversation with a dermatologist about spironolactone is worth having. The drug is not appropriate for everyone — it requires contraception, is only for women, and takes several months to show results — but for the right patient, it addresses the root hormonal cause of breakouts rather than just managing symptoms. As more trial data arrives over the next year, its role in acne treatment is likely to become even more clearly defined.
Frequently Asked Questions
Is spironolactone FDA-approved for acne?
No. Spironolactone is FDA-approved for heart failure, hypertension, hyperaldosteronism, edema, and hypokalemia. Its use for acne is entirely off-label, though it is included in the American Academy of Dermatology’s official treatment guidelines.
How long does spironolactone take to work for acne?
Most patients begin to see improvement after two to three months, with full results typically apparent by six months. It is not a fast-acting treatment, and dermatologists often prescribe topical treatments alongside it during the initial period.
Can men take spironolactone for acne?
No. Spironolactone is only prescribed to women for acne. Its anti-androgen effects would cause breast tissue growth and sexual dysfunction in men, making it contraindicated for male patients.
What is the typical dose of spironolactone for acne?
Most studies and clinical protocols use 100 milligrams per day as the standard dose, though effective doses range from 50 to 200 milligrams daily. Treatment is dose-dependent, meaning higher doses within that range may provide additional benefit.
Will acne come back if I stop taking spironolactone?
In many cases, yes. Because spironolactone addresses hormonal acne by blocking androgen receptors rather than curing the underlying hormonal pattern, breakouts often return when the medication is discontinued. Many women remain on the drug long-term as maintenance therapy.
Does spironolactone cause serious side effects?
Meta-analyses have found no statistically significant increase in side effects like menstrual irregularities or breast tenderness compared to placebo. However, the drug is teratogenic and requires reliable contraception. Women with kidney disease or those taking potassium-raising medications need closer monitoring for elevated potassium levels.
